Dr. David Mankoff
Dr. David Mankoff
I specialize in
I have been in practice
My answers and insights have
Helped 20 people
Here are kind words from others
This Thanksgiving, I wanted to share my appreciation for all that you do! Thank you, doctor! :)
I was educated and trained at
Medical / Graduate School
University of Pennsylvania School of Medicine
University of Pennsylvania
Predicting Breast Cancer Endocrine Responsiveness Using Molecular Imaging.
Curr Breast Cancer Rep., Dec;3(4):205-211 (2011)
Quantitative assessment of dynamic PET imaging data in cancer imaging.
Magn Reson Imaging., Nov;30(9):1203-15 (2012)
Early experiences in establishing a regional quantitative imaging network for PET/CT clinical trials.
Magn Reson Imaging., Nov;30(9):1291-300 (2012)
Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.
J Natl Compr Canc Netw., Jul;10(7):821-9 (2012)
ACR Appropriateness CriteriaÂ® stage I breast carcinoma.
J Am Coll Radiol., Jul;9(7):463-7 (2012)
Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients.
EJNMMI Res., 2(1):34 (2012)
Accuracy of CT-based attenuation correction in PET/CT bone imaging.
Phys Med Biol., May;57(9):2477-90 (2012)
Advances in molecular imaging for breast cancer detection and characterization.
Breast Cancer Res., 14(2):206 (2012)
[Â¹â¸F]fluorodeoxyglucose positron emission tomography-computed tomography in breast cancer: when... and when not?
J. Clin. Oncol., Apr;30(12):1252-4 (2012)
Design considerations for using PET as a response measure in single site and multicenter clinical trials.
Acad Radiol., Feb;19(2):184-90 (2012)
Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.
Nucl. Med. Biol., Oct;38(7):969-78 (2011)
Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.
J. Nucl. Med., Oct;52(10):1541-9 (2011)
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
Clin. Cancer Res., Jul;17(14):4799-805 (2011)
ABNM celebrates 40th anniversary.
J. Nucl. Med., Jul;52(7):17N-8N (2011)
ABNM position statement: Nuclear medicine professional competency and scope of practice.
J. Nucl. Med., Jun;52(6):994-7 (2011)
Multiagent PET for risk characterization in sarcoma.
J. Nucl. Med., Apr;52(4):541-6 (2011)
PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.
Clin. Cancer Res., Apr;17(8):2400-9 (2011)
Invasive breast cancer.
J Natl Compr Canc Netw., Feb;9(2):136-222 (2011)
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.
Clin Nucl Med., Mar;36(3):192-8 (2011)
Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.
J Magn Reson Imaging., Nov;32(5):1124-31 (2010)
Dr. David Mankoff M